期刊文献+

献血者初筛和复检ALT测量值的相关性分析 被引量:2

Correlation Analysis of the ALT Measurements between Donors Screening and Rechecking
下载PDF
导出
摘要 目的探讨献血者初筛和复检ALT测量值的相关性,为献血者初筛ALT上限值界定提供一个可参考的理论依据。方法初筛采用半自动生化分析仪使用一种试剂进行测定,复检采用全自动生化分析仪,用两种试剂进行测定,均为速率法。对4404份标本的测定结果经对数转换后使用SPSS13.0软件SH,GIP=0.935进行统计学分析。结果3次ALT测定结果相比,P〈0.05。而2次复检结果差异无统计学意义(P〉0.05)。初筛ALT测量值x和2次复检测量值y1和Y2的线性回归方程及相关系数分别为:lgYl=0.124+0.868lgX,r=0.901;lgY2=0.116+0.8781gX,r=0.893;依据回归方程推导出对于复栓试剂1和2,初筛ALT水平分别控制在31U/L和30U/L以下,有95%的可能使2种试剂的复检ALT水平不超过40U/L。结论通过统计控制建立了该地无偿献血者初筛上限参考值,最大限度地避免血液浪费,同时也要采取适当的措施保证充足的血源。 Objective To discuss the correlation of the ALT measurements between donors screening and rechecking and provide a reference for the theory basis of ALT upper limit cutoff. Methods A reagent was used to determine ALT in a initial screening by a semi-automatic biochemical analyser. The ALT re-inspection was determined with two reagents by a automatic biochemistry analyser. The rate method was used. The measured results of 4 404 specimens were analysed after conversion by logarithmic using the statistical analysis software SPSS 13.0. Results 3 times ALT determination result were compared (P^0. 05). 2 times re-assessment results were compared (P^0. 05). The liner regression equation and cor- relation coefficient between the ALT screening measured values X and 2 times rechecking(Y1 ,Y2) respcetively were :lgY1 =0. 124+0. 8681gX,r=0. 901 ;lgY2=0. 116+0. 8781gX,r=0. 893. According the regression equation,it was deduced theearly screeing ALT should be respectively controlled below 31 U/L and 30 U/L. 95% of ALT reinspction does not exceed 40 U/L. Conclusion ALT early screeing reference measurement in local blood donors was established through the statictical controlling.
机构地区 邯郸市中心血站
出处 《现代检验医学杂志》 CAS 2011年第1期27-28,共2页 Journal of Modern Laboratory Medicine
关键词 献血者 初筛 复检 丙氨酸氨基转移酶 相关 blood donor early screening rechecking ALT correlation
  • 相关文献

参考文献3

二级参考文献1

共引文献41

同被引文献23

  • 1庄辉.乙型肝炎流行病学研究进展[J].中国医学前沿杂志(电子版),2009,1(2):18-24. 被引量:91
  • 2Raimondo G, Allain J P, Brunetto M P, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection[J]. J Hepatol, 2008, 49(4): 652-657.
  • 3Allain J P, Belkhiri D, Vermeulen M, et al. Characterization of occult hepatitis B virus strains in South African blood donors[J]. Hepatology, 2009, 49(6): 1868-1876.
  • 4Roth W K. Hepatitis B and blood transfusion[J]. ISBT Science Series, 2007, 2(1): 178-183.
  • 5World Health Organization. Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products[J]. WHO Technical Report, 2004, Series 924.
  • 6Kleinman S H, Lelie N, Busch M E Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion[J]. Transfusion, 2009, 49(11): 2454-2489.
  • 7Goodrich R P, Custer B, Keil S, et al. Defining "adequate" pathogen reduction performance for transfused blood components[J]. Transfusion, 2010, 50(8): 1827-1837.
  • 8Hollinger F B, Sood G. Occult hepatitis B virus infection: a covert operation[J]. J Viral Hepat, 2010, 17(1): 1-15.
  • 9Tani Y, Aso H, Matsukura H, et al. Significant background rates of HBV and HCV infections in patients and risks of blood transfusion from donors with low anti-HBc titres or high anti- HBc titres with high anti-HBs titres in Japan: a prospective, individual NAT study of transfusion-transmitted HBV, HCV and HIV infections[J]. Vox Sang, 2012, 102(4): 285-293.
  • 10中华人民共和国卫生部,中国国家标准化管理委员会.献血者健康检查要求[S].

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部